替沃扎尼是一种口服VEGF受体酪氨酸激酶抑制剂。它已经完成了对第一线(治疗幼稚)肾细胞癌患者的治疗三期调查。第一线研究的结果没有得到美国FDA的批准,但替沃扎尼在2017年8月被欧洲药品管理局(EMA)批准。

清空选项
91-16-7 1,2-Dimethoxybenzene
BD15639991-16-797%
¥120.00500g常备现货
35654-56-9 4-Chloro-6,7-dimethoxyquinoline
BD1292835654-56-998%
¥224.0025g常备现货
4101-30-8 1-(2-Amino-4,5-dimethoxyphenyl)ethanone
BD02094101-30-896%
¥120.005g常备现货
1131-62-0 1-(3,4-Dimethoxyphenyl)ethanone
BD820341131-62-098%
¥27.0010g常备现货
4101-32-0 4',5'-Dimethoxy-2'-nitroacetophenone
BD507634101-32-095%
¥796.005g常备现货
127285-54-5 6,7-Dimethoxyquinolin-4(1H)-one
BD01406391127285-54-598%
¥46.001g常备现货
52671-64-4 4-Amino-3-chlorophenol hydrochloride
BD4176252671-64-498%
¥135.0025g常备现货
1072-67-9 5-Methylisoxazol-3-amine
BD174621072-67-997%
¥74.0010g常备现货
286371-44-6 2-Chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)aniline
BD763846286371-44-697%
¥19677.001g
1